Having explored adult urticaria, in this section of the Knowledge Centre, we review the available data in paediatric urticaria and establish the impact it has on younger patients and how diagnosis and management compares to the recommendations for adult patients with CSU.
Learn from our paediatric CSU expert Dr Montserrat Álvaro, who discussed a number of key topics important for managing paediatric CSU in a recent interview. Watch short clips from the interview which introduce chronic urticaria in childhood, discuss the epidemiology and impact of paediatric urticaria and how to ask the right questions and use tests when diagnosing urticaria in paediatric patients. Dr Álvaro discusses the challenge of managing paediatric patients, the key clinical studies and how to treat patients who remain symptomatic. Dr Álvaro also answers some frequently asked questions about paediatric CSU. More recently, Dr Álvaro presented a paediatric patient case study at the EAACI 2019 Congress which took place in Lisbon. The full video can be viewed here .
How do the comorbidities of paediatric and adolescent patients with CSU compare to adult patients? Learn more about the conditions that commonly affect infants, children and adolescents with CSU.
Explore the life-changing detrimental effects that urticaria can have on children’s quality of life (CLQI) compared with other diseases such as cerebral palsy, eczema, asthma, diabetes and epilepsy, and watch a video of Doctor Montse Alvaro.
When and why certain diagnostic tests are used in diagnosing urticaria. Tests include complete blood count; erythrocyte sedimentation rate, C-reactive protein, thyroid antibody, thyroid function test, antinuclear antibody and autologous serum skin test.
Learn about the three lines of treatment management that are used in paediatric urticaria where it is strongly recommended that first-generation H1-antihistamines are not prescribed to infants and children.